# EDGAR Filing Document

**Accession Number:** 0002028614
**File Stem:** 0001213900-26-035502
**Filing Date:** 2026-3
**Character Count:** 15520
**Document Hash:** ff7268574a272f2d802e31406a6434b7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-035502.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001213900-26-035502

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260323

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition Corp.
- **CENTRAL INDEX KEY:** 0002028614
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42467
- **FILM NUMBER:** 26807323

**BUSINESS ADDRESS:**
- **STREET 1:** 2 PELICAN DR.
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3104

**MAIL ADDRESS:**
- **STREET 1:** 2 PELICAN DR.
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d) of the**

**Securities Exchange Act of 1934**

**March 23, 2026**

Date of Report (Date of earliest event reported)

**Drugs Made In America Acquisition Corp.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-42467** | **99-2394788** |
| (State or Other Jurisdiction <br> of Incorporation) | (Commission File Number) | (I.R.S. Employer <br> Identification Number) |

---

---

| | |
|:---|:---|
| **1 East Broward Boulevard, Suite 700**<br> **Fort Lauderdale, FL** | **33301** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**646-726-7074**

Registrant's telephone number, including area code:

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Units, each consisting of one Ordinary share, $0.0001 par value and one right to receive one-eighth of one ordinary share | DMAAU | The Nasdaq Stock Market LLC |
| Ordinary shares, par value $0.0001 per share | DMAA | The Nasdaq Stock Market LLC |
| Rights, each entitling the holder to receive one-eighth of one Ordinary Share | DMAAR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 23, 2026, Drugs Made In America Acquisition Corp. (the "**Company**") issued an interim convertible note (the "**Interim Note**") to BV Advisory Partners, LLC (the "**Investor**") in the principal amount of $100,000 (the "**Interim Loan**"). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the "**Financing**") pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the "**Investment Agreement**") described under Item 8.01 of this Current Report on Form 8-K.

The Interim Note has a maturity date six months from the date of issuance, unless earlier converted or credited toward the definitive financing under the Investment Agreement and does not bear interest. Upon the consummation of initial business combination by the Company (a "**Business Combination**"), the outstanding principal amount of the Interim Loan may, at the option of the Investor, be converted into shares of the combined entity at a conversion price equal to a 35% discount to the market price of such shares at the time of conversion.

The Company intends to use the proceeds of the Interim Loan for accounting expenses, audit expenses and other expenses related to a Business Combination although it has not yet entered into an agreement for a Business Combination.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the issuance of the Interim Loan is incorporated herein by reference.

The Interim Loan represents a direct financial obligation of the Company. The Interim Loan is filed as Exhibit 10.3 hereto and is incorporated herein by reference.

**Item 8.01 Other Events**

On March 23, 2026, the Company entered into the Investment Agreement with the Investor relating to a proposed financing transaction pursuant to which the Investor indicated its intent to provide financing to the Company through a convertible note investment, of which the Interim Loan represented the first tranche. Pursuant to the Investment Agreement, the aggregate amount to be loaned is $500,000. The second tranche of $200,000 will be made within 21 days with the remainder of the commitment on an as-needed basis. The Company also agreed to use commercially reasonable efforts to provide the Investor with not less than 40% of the economic benefit equivalent to sponsor-level economics. The Investor has the right but not the obligation to provide additional funding beyond the $500,000 commitment.

In connection with the Investment Agreement, the Investor has introduced to the Company a potential business combination opportunity involving an enterprise technology platform focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions, consistent with the business of Power Analytics Global Corporation.

The Company has commenced preliminary due diligence with respect to this potential opportunity. As of the date of this report, no letter of intent, term sheet, or definitive agreement has been executed, and there can be no assurance that any business combination will result from this evaluation.

The foregoing description of the Investment Agreement and Interim Loan is not complete and is qualified in its entirety by reference to the full text of the Investment Agreement and Interim Loan, copies of which are filed hereto as Exhibit 10.1 and Exhibit 10.2, respectively.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 10.1 | [Definitive Interim Investment and Sponsor Transition Agreement](ea028380301ex10-1.htm) |
| 10.2 | [Interim Convertible Note](ea028380301ex10-2.htm) |
| 104 | Cover Page Interactive Data File |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 27, 2026

---

| | |
|:---|:---|
| **DRUGS MADE IN AMERICA ACQUISITION CORP.** | **DRUGS MADE IN AMERICA ACQUISITION CORP.** |
| By: | /s/ Roger Bendelac |
| Name: | Roger Bendelac |
| Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

<u>DEFINITIVE INTERIM INVESTMENT AND SPONSOR TRANSITION AGREEMENT</u>

Drugs Made in America Acquisition Corp. I (Cayman Islands)

Date: March 23, 2026

1. **Parties**

This Agreement is entered into between:

BV Advisory Partners, LLC

903 Hudson Street

Hoboken, NJ 07030 (the "Investor")

and

Drugs Made in America Acquisition Corp. I (the "Company").

2. **Background**

The Company confirms that its sponsor entity, Drugs Made in America Acquisition LLC, is non-operational and subject to legal constraints.

The Investor is introducing a specific target transaction involving an enterprise AI & ML, Quantum analytics, and cybersecurity platform business consistent with the Power Analytics Global Corporation opportunity, including integrated AI & ML analytics, cloud, quantum, and cybersecurity technologies.

The Company is pursuing a replacement sponsor and transaction aligned with this introduced opportunity.

3. **Investment Commitment**

The Investor shall provide:

- $100,000 immediately;

- $200,000 within twenty-one (21) days;

- up to $500,000 total commitment as required.

Funds shall be used for compliance, Nasdaq, audit, legal and transaction preparation.

4. **Interim Convertible Note**

The initial $100,000 shall:

- be deposited into the IOLA account of Thomas J. McCabe, Attorney at Law;

- be convertible at the sole discretion of the Investor;

- convert at a 35% discount to post-merger market value;

- have a maturity of six (6) months;

- not constitute a claim against the trust account.

5. **Sponsor Economics and Transition**

The Company shall use good faith and commercially reasonable efforts to provide the Investor with not less than 40% of the economic benefit equivalent to sponsor-level economics.

Such economics may be achieved through issuance of new securities, reallocation when legally permissible, or other agreed structures.

The Company shall assist in good faith negotiations for transfer of sponsor interests when legally permissible.

6. **Timeline and Milestones**

Within six (6) months:

- advance the specific introduced transaction;

- execute an agreement in principle (LOI / term sheet);

- progress toward a business combination.

The Company shall pursue extension via proxy and engage its investment bank to renegotiate underwriting fees.

7. **Additional Funding and Rights**

The Investor shall have the right, but not obligation, to provide additional financing including extension funding, PIPE, or acquisition financing, with enhanced participation.

8. **Exclusivity**

Exclusivity is conditioned on funding, and shall be triggered upon receipt of initial bridge funding amount. If Investor fails to fund, Company may seek third-party financing while preserving

Investor participation rights where practicable.

9. **Governance**

Investor shall receive information rights and be consulted on material financing and transaction decisions.

10. **Governing Law**

This Agreement shall be governed by Cayman Islands law with New York and/ or New Jersey courts for enforcement.

11. **Binding Effect**

This Agreement reflects the definitive understanding of the parties, subject to customary Board ratification.

SIGNATURES

---

| | |
|:---|:---|
| BV ADVISORY PARTNERS, LLC | BV ADVISORY PARTNERS, LLC |
| By: | /s/ Keith Barksdale |
| Name: | Keith Barksdale |
| Title: | Managing Member |
| DRUGS MADE IN AMERICA ACQUISITION CORP. I | DRUGS MADE IN AMERICA ACQUISITION CORP. I |
| By: | /S/ Roger Bendelac |
| Name: | Roger Bendelac |
| Title: | CEO |

---

## Exhibit 10.2

**Exhibit 10.2**

<u>INTERIM CONVERTIBLE NOTE</u>

Issuer: Drugs Made in America Acquisition Corp. I

Principal Amount: $100,000

Date: March 23, 2026

1. **Purpose**

This Interim Convertible Note represents bridge financing provided by the Investor to cover accounting, audit, Nasdaq compliance, legal, and regulatory reporting expenses required for the Company to remain compliant and to advance the contemplated transaction and extension process.

2. **Relationship to Main Financing**

This Note serves as the initial funding component of the proposed financing arrangement between BV Advisory Partners, LLC and/or affiliates, and Drugs Made in America Acquisition Corp. I, and shall be credited toward the broader commitment of up to $500,000 contemplated by the parties under the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026.

3. **Funding and Deposit**

The principal amount of this Note shall be funded by wire transfer to the IOLA account of Thomas J. McCabe, Attorney at Law, for the benefit of the Company, as follows:

Account Name: Thomas J. McCabe, Attorney at Law IOLA

Bank Name: TD Bank, N.A.

Branch: Long Beach Road

Bank Address: Oceanside, New York

ABA / Routing Number: 026013673 Account Number: 4361730611

Reference / Memo: BV Advisory Partners, LLC – DMAA I Interim Funding

This Note shall become effective upon credit of funds to such account or to any successor account designated in writing by the Company or The McCabe Law Firm, P.C. for the Company's benefit.

4. **Use of Proceeds**

Proceeds of this Note shall be used exclusively for accounting, audit, Nasdaq compliance, legal, proxy, extension, and other regulatory and transaction-related expenses of the Company.

5. **Conversion**

Conversion shall occur solely at the discretion of the lender after completion of the Company's business combination transaction.

In the event of such occurrence, the outstanding principal amount may be converted into shares or equivalent equity interests of the post-merger combined entity at a price reflecting a thirty-five percent (35%) discount to the market value of such securities at the time of conversion.

6. **No Claim Against Trust Account**

This Note shall not constitute, and the Investor expressly acknowledges that it does not create, any claim against the Company's trust account. Repayment, conversion, or other treatment of this Note shall be independent of the trust account and subject only to the terms agreed between the parties.

7. **Maturity**

This Note shall mature six (6) months from the date of issuance, unless earlier converted, repaid, or credited toward definitive financing documentation between the parties.

8. **Governing Law and Jurisdiction**

This Note shall be governed by the laws of the Cayman Islands.

For enforcement and dispute resolution, the courts of the State of New York or the State of New Jersey, USA, shall have jurisdiction. The parties acknowledge that Cayman Islands corporate law principles shall apply where relevant to corporate matters of the Issuer.

9. **Binding Effect**

This Note shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

Signatures

Investor

---

| | |
|:---|:---|
| BV Advisory Partners, LLC | BV Advisory Partners, LLC |
| By: | /s/ Keith Barksdale |
| Name: | Keith Barksdale |
| Title: | Managing Member |
| Date: | March 23, 2026 |
| Drugs Made in America Acquisition Corp. | Drugs Made in America Acquisition Corp. |
| By: | /s/ Roger E. Bendelac |
| Name: | Roger E. Bendelac |
| Title: | Chief Executive Officer |
| Date: | 03/23/2026 |

---